Free Trial

VYNE Therapeutics (VYNE) Competitors

VYNE Therapeutics logo
$1.38 -0.13 (-8.61%)
Closing price 07/3/2025 03:58 PM Eastern
Extended Trading
$1.42 +0.05 (+3.26%)
As of 07/3/2025 04:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

VYNE vs. VRCA, KRON, HOWL, IFRX, DTIL, GANX, CUE, TELO, AADI, and CNTX

Should you be buying VYNE Therapeutics stock or one of its competitors? The main competitors of VYNE Therapeutics include Verrica Pharmaceuticals (VRCA), Kronos Bio (KRON), Werewolf Therapeutics (HOWL), InflaRx (IFRX), Precision BioSciences (DTIL), Gain Therapeutics (GANX), Cue Biopharma (CUE), Telomir Pharmaceuticals (TELO), Aadi Bioscience (AADI), and Context Therapeutics (CNTX). These companies are all part of the "pharmaceutical products" industry.

VYNE Therapeutics vs. Its Competitors

Verrica Pharmaceuticals (NASDAQ:VRCA) and VYNE Therapeutics (NASDAQ:VYNE) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, valuation, media sentiment, dividends, profitability, analyst recommendations, institutional ownership and risk.

Verrica Pharmaceuticals has a net margin of 0.00% compared to VYNE Therapeutics' net margin of -6,974.55%. Verrica Pharmaceuticals' return on equity of 0.00% beat VYNE Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Verrica PharmaceuticalsN/A N/A -145.63%
VYNE Therapeutics -6,974.55%-71.89%-58.94%

VYNE Therapeutics has lower revenue, but higher earnings than Verrica Pharmaceuticals. VYNE Therapeutics is trading at a lower price-to-earnings ratio than Verrica Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Verrica Pharmaceuticals$7.57M8.41-$76.58M-$1.20-0.57
VYNE Therapeutics$500K41.98-$39.83M-$0.99-1.39

Verrica Pharmaceuticals has a beta of 1.76, suggesting that its share price is 76% more volatile than the S&P 500. Comparatively, VYNE Therapeutics has a beta of 1.78, suggesting that its share price is 78% more volatile than the S&P 500.

42.5% of Verrica Pharmaceuticals shares are held by institutional investors. Comparatively, 83.8% of VYNE Therapeutics shares are held by institutional investors. 54.0% of Verrica Pharmaceuticals shares are held by insiders. Comparatively, 4.8% of VYNE Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, VYNE Therapeutics had 1 more articles in the media than Verrica Pharmaceuticals. MarketBeat recorded 2 mentions for VYNE Therapeutics and 1 mentions for Verrica Pharmaceuticals. VYNE Therapeutics' average media sentiment score of 1.04 beat Verrica Pharmaceuticals' score of 0.00 indicating that VYNE Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Verrica Pharmaceuticals
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
VYNE Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Verrica Pharmaceuticals presently has a consensus target price of $8.00, indicating a potential upside of 1,062.79%. VYNE Therapeutics has a consensus target price of $6.25, indicating a potential upside of 352.90%. Given Verrica Pharmaceuticals' higher probable upside, analysts clearly believe Verrica Pharmaceuticals is more favorable than VYNE Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Verrica Pharmaceuticals
0 Sell rating(s)
4 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.20
VYNE Therapeutics
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00

Summary

VYNE Therapeutics beats Verrica Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

Get VYNE Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for VYNE and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VYNE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

VYNE vs. The Competition

MetricVYNE TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$21.67M$2.43B$5.56B$9.04B
Dividend YieldN/A1.78%5.24%4.01%
P/E Ratio-1.399.1027.6120.24
Price / Sales41.98680.45417.30118.22
Price / CashN/A158.5936.8958.10
Price / Book0.394.588.035.67
Net Income-$39.83M$31.34M$3.18B$249.21M
7 Day Performance-2.82%3.25%2.93%3.28%
1 Month Performance38.00%7.08%3.75%5.55%
1 Year Performance-25.00%0.17%35.20%21.09%

VYNE Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
VYNE
VYNE Therapeutics
3.0851 of 5 stars
$1.38
-8.6%
$6.25
+352.9%
-24.6%$21.67M$500K-1.3930Positive News
High Trading Volume
VRCA
Verrica Pharmaceuticals
3.6419 of 5 stars
$0.59
+0.4%
$8.00
+1,262.2%
-90.8%$54.09M$7.57M-0.4940
KRON
Kronos Bio
3.483 of 5 stars
$0.88
+1.5%
$1.63
+84.7%
-22.1%$53.72M$9.85M-0.82100
HOWL
Werewolf Therapeutics
3.0903 of 5 stars
$1.25
+5.0%
$8.33
+566.7%
-49.5%$53.40M$1.88M-0.7540News Coverage
IFRX
InflaRx
2.6808 of 5 stars
$0.79
-0.3%
$6.60
+732.3%
-50.6%$53.38M$180K-0.9760News Coverage
DTIL
Precision BioSciences
4.5741 of 5 stars
$4.53
-5.4%
$47.00
+937.5%
-52.9%$53.11M$68.70M-2.25200
GANX
Gain Therapeutics
3.0556 of 5 stars
$1.69
-4.5%
$8.20
+385.2%
+45.7%$53.00M$50K-1.9720News Coverage
Analyst Forecast
Gap Down
CUE
Cue Biopharma
4.0914 of 5 stars
$0.65
-7.2%
$3.00
+361.5%
-29.8%$52.80M$9.29M-0.9760News Coverage
Gap Down
TELO
Telomir Pharmaceuticals
2.8056 of 5 stars
$1.69
-4.0%
$15.00
+787.6%
-68.5%$52.38MN/A-4.021
AADI
Aadi Bioscience
0.6452 of 5 stars
$2.09
+2.0%
$1.67
-20.3%
+42.1%$51.62M$25.07M-0.9240News Coverage
High Trading Volume
CNTX
Context Therapeutics
3.0128 of 5 stars
$0.56
-1.6%
$6.00
+965.0%
-63.4%$51.37MN/A-1.827

Related Companies and Tools


This page (NASDAQ:VYNE) was last updated on 7/5/2025 by MarketBeat.com Staff
From Our Partners